First Patient Dosed in Phase 2b Clinical Trial of IVW-1001 for Dry Eye Disease
IVIEW Therapeutics today announced that the first patient has been dosed in its Phase 2b clinical trial evaluating IVW-1001, a novel topical therapy for dry eye disease. The initial dosing was conducted at the Eye Research Foundation in Newport Beach, California.
IVW-1001 eyelid wipe is an eyelid wipe saturated with the novel New Chemical Entity (NCE), a selective TRPM8 agonist, for the treatment of dry eye disease. This product is differentiated from the traditional eye drop delivery, designed to deliver the drug to targeted TRPM8 receptor under the eyelid margin directly. The Phase 2b study will further evaluate its safety, tolerability, and efficacy with optimization of the eyelid application techniques, building on encouraging data from earlier phase 1/2a trials.
“It is truly exciting to begin this Phase 2b clinical trial of IVW-1001,” said David Wirta, M.D., Principal Investigator and Medical Director at the Eye Research Foundation. “We look forward to advancing this study and exploring the potential of this novel therapy to make a real difference for patients living with dry eye disease.”
Dry eye disease is a widespread condition that significantly impacts quality of life for millions of patients worldwide. IVW-1001, developed by IVIEW Therapeutics, is a TRPM8 agonist designed to address the underlying drivers of the disease. Its unique wipe-based eyelid delivery system provides a novel approach that sets it apart as a potentially transformative therapy.
“Our goal is to bring forward new treatment options for patients with dry eye disease,” said Bo Liang, PhD, MBA, Co-founder, Chairman, and CEO of IVIEW Therapeutics Inc. “This milestone is an important step, made possible through the dedication of our clinical teams and partners.”
About IVIEW Therapeutics Inc.
IVIEW Therapeutics Inc. is a clinical-stage biotechnology company focused on developing innovative ophthalmic therapies. We invest in novel mechanisms of action and differentiated drug delivery platforms to create therapies with superior clinical profiles that address significant unmet medical needs. Our pipeline includes small molecules and gene therapies for dry eye, myopia, conjunctivitis, glaucoma, and presbyopia. The U.S. headquarters is located in Cranbury, New Jersey, with 11,045 square feet of combined laboratory and office space in the Princeton area.
For additional information, please visit www.iviewtherapeutics.com
Media Contact:
Wei Wang, PhD, Head of Operations
Email: weiwang@iviewinc.com